National

ETV Bharat / international

UK signs deals for 90mn COVID-19 vaccine doses

Britain said that it had secured access to a vaccine candidate being developed by Pfizer and BioNTech, in addition to another experimental vaccine researched by Valneva. The UK had previously signed a deal with AstraZeneca to provide 100 million doses of the coronavirus vaccine being tested by Oxford University, which is expected to announce further results later on Monday.

Vaccine
Representative image

By

Published : Jul 20, 2020, 5:14 PM IST

London: Britain has signed deals for 90 million doses of promising coronavirus vaccines that are being developed, media reports said on Monday.

The vaccines are being researched by an alliance between the pharmaceutical companies BioNtech and Pfizer as well as the firm Valneva, reported the BBC.

The new deal is on top of 100 million doses of the Oxford University vaccine being developed by AstraZeneca. However, it's still uncertain which of the experimental vaccines may work.

Read also:Chinese company boasts it tested vaccine on execs

"The fact that we have so many promising candidates already shows the unprecedented pace at which we are moving," the BBC quoted Kate Bingham, the chair of the government's Vaccine Taskforce, as saying.

"But I urge against being complacent or over-optimistic." "The fact remains we may never get a vaccine and if we do get one, we have to be prepared that it may not be a vaccine which prevents getting the virus, but rather one that reduces symptoms," she added.

Read also:99% sure coronavirus vaccine will work, claim Chinese scientists

Meanwhile, Education Secretary Gavin Williamson told the BBC on Monday morning that vaccine development was "an incredibly long process and we are doing it at breakneck speed" but that we should expect a COVID-19 vaccine "after winter".

The government is hoping to get half a million people to sign up for vaccine trials in the UK.

At least eight large scale coronavirus vaccine trials are expected to take place in the UK.

IANS

ABOUT THE AUTHOR

...view details